Studying furosemide solubilization using an in vitro model simulating gastrointestinal digestion and drug solubilization in neonates and young infants
The aim of the present study was to study the oral performance of furosemide in neonates and young infants using a newly developed in vitro model simulating digestion and drug solubilization in the gastrointestinal (GI) tract of the human neonate and young infant population (age 0–2months). The util...
Saved in:
Published in | European journal of pharmaceutical sciences Vol. 109; pp. 191 - 199 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
Elsevier B.V
15.11.2017
|
Subjects | |
Online Access | Get full text |
ISSN | 0928-0987 1879-0720 1879-0720 |
DOI | 10.1016/j.ejps.2017.08.003 |
Cover
Abstract | The aim of the present study was to study the oral performance of furosemide in neonates and young infants using a newly developed in vitro model simulating digestion and drug solubilization in the gastrointestinal (GI) tract of the human neonate and young infant population (age 0–2months).
The utilized in vitro model was designed to mimic the digestion and drug solubilization processes occurring in the stomach, and the small intestine of the neonate and young infant population, using physiologically relevant media, volumes and digestive enzymes. Overall the experimental model setup was based on the dynamic in vitro lipolysis model previously described by Fernandez et al. (2009). The amount of furosemide solubilized in the aqueous phase during a digestion study was used as an estimate for the amount of drug available for absorption in vivo. By varying different factors in the model setup, e.g. presence of food (food-effect), effect of digestion (tested with and without addition of digestive enzymes), and properties of the dosage form, it was possible to estimate the importance of these factors in vivo.
The present in vitro data suggest that the oral performance of furosemide in neonates and young infants will be increased by the presence of food (frequent feedings) due to increased drug solubilization, however, not influenced by the GI digestion of this food. The properties of the dosage form (immediate release tablets) did not affect the drug solubilization as compared to administration of the pure drug powder.
[Display omitted] |
---|---|
AbstractList | The aim of the present study was to study the oral performance of furosemide in neonates and young infants using a newly developed in vitro model simulating digestion and drug solubilization in the gastrointestinal (GI) tract of the human neonate and young infant population (age 0–2months).
The utilized in vitro model was designed to mimic the digestion and drug solubilization processes occurring in the stomach, and the small intestine of the neonate and young infant population, using physiologically relevant media, volumes and digestive enzymes. Overall the experimental model setup was based on the dynamic in vitro lipolysis model previously described by Fernandez et al. (2009). The amount of furosemide solubilized in the aqueous phase during a digestion study was used as an estimate for the amount of drug available for absorption in vivo. By varying different factors in the model setup, e.g. presence of food (food-effect), effect of digestion (tested with and without addition of digestive enzymes), and properties of the dosage form, it was possible to estimate the importance of these factors in vivo.
The present in vitro data suggest that the oral performance of furosemide in neonates and young infants will be increased by the presence of food (frequent feedings) due to increased drug solubilization, however, not influenced by the GI digestion of this food. The properties of the dosage form (immediate release tablets) did not affect the drug solubilization as compared to administration of the pure drug powder.
[Display omitted] The aim of the present study was to study the oral performance of furosemide in neonates and young infants using a newly developed in vitro model simulating digestion and drug solubilization in the gastrointestinal (GI) tract of the human neonate and young infant population (age 0-2months).OBJECTIVEThe aim of the present study was to study the oral performance of furosemide in neonates and young infants using a newly developed in vitro model simulating digestion and drug solubilization in the gastrointestinal (GI) tract of the human neonate and young infant population (age 0-2months).The utilized in vitro model was designed to mimic the digestion and drug solubilization processes occurring in the stomach, and the small intestine of the neonate and young infant population, using physiologically relevant media, volumes and digestive enzymes. Overall the experimental model setup was based on the dynamic in vitro lipolysis model previously described by Fernandez et al. (2009). The amount of furosemide solubilized in the aqueous phase during a digestion study was used as an estimate for the amount of drug available for absorption in vivo. By varying different factors in the model setup, e.g. presence of food (food-effect), effect of digestion (tested with and without addition of digestive enzymes), and properties of the dosage form, it was possible to estimate the importance of these factors in vivo.METHODSThe utilized in vitro model was designed to mimic the digestion and drug solubilization processes occurring in the stomach, and the small intestine of the neonate and young infant population, using physiologically relevant media, volumes and digestive enzymes. Overall the experimental model setup was based on the dynamic in vitro lipolysis model previously described by Fernandez et al. (2009). The amount of furosemide solubilized in the aqueous phase during a digestion study was used as an estimate for the amount of drug available for absorption in vivo. By varying different factors in the model setup, e.g. presence of food (food-effect), effect of digestion (tested with and without addition of digestive enzymes), and properties of the dosage form, it was possible to estimate the importance of these factors in vivo.The present in vitro data suggest that the oral performance of furosemide in neonates and young infants will be increased by the presence of food (frequent feedings) due to increased drug solubilization, however, not influenced by the GI digestion of this food. The properties of the dosage form (immediate release tablets) did not affect the drug solubilization as compared to administration of the pure drug powder.KEY FINDINGS AND CONCLUSIONSThe present in vitro data suggest that the oral performance of furosemide in neonates and young infants will be increased by the presence of food (frequent feedings) due to increased drug solubilization, however, not influenced by the GI digestion of this food. The properties of the dosage form (immediate release tablets) did not affect the drug solubilization as compared to administration of the pure drug powder. The aim of the present study was to study the oral performance of furosemide in neonates and young infants using a newly developed in vitro model simulating digestion and drug solubilization in the gastrointestinal (GI) tract of the human neonate and young infant population (age 0-2months). The utilized in vitro model was designed to mimic the digestion and drug solubilization processes occurring in the stomach, and the small intestine of the neonate and young infant population, using physiologically relevant media, volumes and digestive enzymes. Overall the experimental model setup was based on the dynamic in vitro lipolysis model previously described by Fernandez et al. (2009). The amount of furosemide solubilized in the aqueous phase during a digestion study was used as an estimate for the amount of drug available for absorption in vivo. By varying different factors in the model setup, e.g. presence of food (food-effect), effect of digestion (tested with and without addition of digestive enzymes), and properties of the dosage form, it was possible to estimate the importance of these factors in vivo. The present in vitro data suggest that the oral performance of furosemide in neonates and young infants will be increased by the presence of food (frequent feedings) due to increased drug solubilization, however, not influenced by the GI digestion of this food. The properties of the dosage form (immediate release tablets) did not affect the drug solubilization as compared to administration of the pure drug powder. |
Author | Selen, Arzu Müllertz, Anette Berthelsen, Ragna Klitgaard, Mette Sassene, Philip Jonas |
Author_xml | – sequence: 1 givenname: Mette surname: Klitgaard fullname: Klitgaard, Mette email: sfv995@sund.ku.dk organization: Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark – sequence: 2 givenname: Philip Jonas surname: Sassene fullname: Sassene, Philip Jonas email: dlt527@alumni.ku.dk organization: Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark – sequence: 3 givenname: Arzu surname: Selen fullname: Selen, Arzu email: arzu.Selen@fda.hhs.gov organization: Office of Testing and Research, US Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, United States – sequence: 4 givenname: Anette surname: Müllertz fullname: Müllertz, Anette email: anette.mullertz@sund.ku.dk organization: Bioneer:FARMA, Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark – sequence: 5 givenname: Ragna orcidid: 0000-0002-5992-9688 surname: Berthelsen fullname: Berthelsen, Ragna email: ragna.berthelsen@sund.ku.dk organization: Department of Pharmacy, University of Copenhagen, Copenhagen, Denmark |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28803922$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUtv1DAUhS1URKeFP8ACZckm4dp52JHYoIqXVIkFsLac-GZ0R4k92HGl4Yfwe3E67aaLrvy45zuyz7liF847ZOwth4oD7z4cKjwcYyWAywpUBVC_YDuuZF-CFHDBdtALVUKv5CW7ivEAAJ2S8IpdCqWg7oXYsX8_12RP5PbFlIKPuJDFIvo5DTTTX7OSd0WK29y4glxxR2vwxeItzkWkJc1Zkod7E_M9uRVjPpu5sLTftpk2zhY2pP1T12zm0DuTkXvNyadsRG4ybo2v2cvJzBHfPKzX7PeXz79uvpW3P75-v_l0W451260lHwaU2GKrBo7WSNENk-jGusF-mKTktm94Y1SeGOgaVA0Mth0Ehw5bsD3W1-z92fcY_J-UX6wXiiPOs8lvS1HznKBUAmqVpe8epGlY0OpjoMWEk37MMgvUWTDmIGPASY-03v91DYZmzUFvtemD3mrTW20alM61ZVQ8QR_dn4U-niHMAd0RBh1HQjeipYDjqq2n5_D_R0O2bw |
CitedBy_id | crossref_primary_10_1039_D0FO01981J crossref_primary_10_1016_j_addr_2019_03_005 crossref_primary_10_1016_j_tifs_2023_104306 crossref_primary_10_3390_pharmaceutics12040365 crossref_primary_10_1111_jphp_12955 crossref_primary_10_1016_j_ejps_2021_105828 crossref_primary_10_3389_fimmu_2018_01098 crossref_primary_10_1016_j_foodchem_2024_142151 crossref_primary_10_1146_annurev_food_060721_025159 crossref_primary_10_1016_j_ijpharm_2024_124286 crossref_primary_10_1016_j_cis_2023_103028 crossref_primary_10_1016_j_apsb_2021_03_025 crossref_primary_10_1039_D0FO02976A crossref_primary_10_1016_j_addr_2019_06_010 |
Cites_doi | 10.1208/s12248-014-9672-x 10.1517/17425255.2012.698261 10.1136/adc.37.194.387 10.1542/peds.72.5.677 10.1016/j.ejps.2015.05.023 10.1016/j.biochi.2015.11.016 10.3390/pharmaceutics2040364 10.1080/10408398.2011.640757 10.1039/C6FO00158K 10.1038/nrd2197 10.1002/jps.23205 10.1002/jps.22030 10.1007/s11095-009-9906-2 10.1016/0009-8981(59)90030-0 10.1007/BF00615967 10.1016/j.ijpharm.2013.07.053 10.1016/0016-5085(93)90908-U 10.1016/j.jpba.2013.05.011 10.1023/A:1016212804288 10.1542/peds.62.5.811 10.1111/jphp.12365 10.1023/A:1011984216775 10.1159/000244419 10.1203/00006450-199609000-00011 |
ContentType | Journal Article |
Copyright | 2017 Elsevier B.V. Copyright © 2017 Elsevier B.V. All rights reserved. |
Copyright_xml | – notice: 2017 Elsevier B.V. – notice: Copyright © 2017 Elsevier B.V. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.ejps.2017.08.003 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1879-0720 |
EndPage | 199 |
ExternalDocumentID | 28803922 10_1016_j_ejps_2017_08_003 S0928098717304475 |
Genre | Journal Article |
GroupedDBID | --- --K --M .~1 0R~ 1B1 1RT 1~. 1~5 4.4 457 4G. 53G 5GY 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AATCM AAXUO ABFRF ABJNI ABLJU ABMAC ABYKQ ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AIEXJ AIKHN AITUG AJBFU AJOXV ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC C45 CS3 DU5 EBS EFJIC EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q GBLVA GROUPED_DOAJ IHE J1W KOM M34 M41 MO0 N9A O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 RIG ROL RPZ SCC SDF SDG SDP SES SPCBC SSP SSZ T5K TEORI ~G- 29G 5VS AAQFI AAQXK AATTM AAXKI AAYWO AAYXX ABFNM ABWVN ABXDB ACRPL ACVFH ADCNI ADMUD ADNMO ADPDF ADVLN AEIPS AEUPX AFJKZ AFPUW AGCQF AGQPQ AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP ASPBG AVWKF AZFZN BNPGV CITATION FEDTE FGOYB G-2 HMT HVGLF HZ~ OK1 R2- SEW SPT SSH WUQ CGR CUY CVF ECM EIF NPM 7X8 EFKBS |
ID | FETCH-LOGICAL-c356t-1bbe7e5e58b1eda726bf26c34e9bf771d9414a8da7a064e840bd5b2106e50d9e3 |
IEDL.DBID | AIKHN |
ISSN | 0928-0987 1879-0720 |
IngestDate | Fri Sep 05 10:43:55 EDT 2025 Thu Apr 03 06:55:59 EDT 2025 Tue Jul 01 02:04:16 EDT 2025 Thu Apr 24 22:58:35 EDT 2025 Fri Feb 23 02:19:42 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | In vitro models Digestion Pediatric Drug solubilization Furosemide Neonates and young infants |
Language | English |
License | Copyright © 2017 Elsevier B.V. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c356t-1bbe7e5e58b1eda726bf26c34e9bf771d9414a8da7a064e840bd5b2106e50d9e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-5992-9688 |
PMID | 28803922 |
PQID | 1928782038 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_1928782038 pubmed_primary_28803922 crossref_citationtrail_10_1016_j_ejps_2017_08_003 crossref_primary_10_1016_j_ejps_2017_08_003 elsevier_sciencedirect_doi_10_1016_j_ejps_2017_08_003 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2017-11-15 |
PublicationDateYYYYMMDD | 2017-11-15 |
PublicationDate_xml | – month: 11 year: 2017 text: 2017-11-15 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | European journal of pharmaceutical sciences |
PublicationTitleAlternate | Eur J Pharm Sci |
PublicationYear | 2017 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Kassab (bb0130) 2015; 11 U.S.Department of Health and Human Services Food and Drug Administration (bb0180) 2005 Havenaar (bb0110) 2013; 457 Zisowsky (bb0195) 2010; 2 Amidon (bb0020) 1995; 12 Administration USDoHaHSFaD (bb0005) 2001 Takacs-Novak (bb0170) 2013; 83 Administration USDoHaHSFaD (bb0015) March 2016 Mason (bb0135) 1962; 37 Armand (bb0025) 1996; 40 Otsuka (bb0150) 2015; 67 Sassene (bb0160) 2014; 16 Mooij (bb0140) 2012; 8 Nestlé (bb0145) Carriere (bb0055) 2016; 125 Beermann, Midskov (bb0030) 1986; 29 European Medicines Agency (bb0080) 2006 European Medicines Agency (bb0085) 2007 U.S.Department of Health and Human Services Food and Drug Administration (bb0185) 2015 Berthelsen (bb0035) 2016 Engle (bb0075) 1978; 62 Administration USDoHaHSFaD (bb0010) 2014 Dressman (bb0065) 1998; 15 Boehm (bb0040) 1997; 71 Frusol (bb0095) 2015 Williams (bb0190) 2012; 101 Encrantz, Sjövall (bb0070) 1959; 4 Hens (bb0115) 2015; 77 Sassene (bb0165) 2016; 7 Kamstrup (bb0125) 2016 Carriere (bb0060) 1993; 105 European Medicines Agency (bb0090) 2016 Granero (bb0105) 2010; 99 Fernandez (bb2015) 2009; 26 Furix (bb0100) 2013 Jarvenpaa (bb0120) 1983; 72 Buck (bb0050) 2009; 15 Porter (bb0155) 2007; 6 The European Commision. Better Medicines for Children From Concept to Reality (bb0175) 2013; 443 Bourlieu (bb0045) 2014; 54 Mooij (10.1016/j.ejps.2017.08.003_bb0140) 2012; 8 Nestlé (10.1016/j.ejps.2017.08.003_bb0145) Carriere (10.1016/j.ejps.2017.08.003_bb0060) 1993; 105 Havenaar (10.1016/j.ejps.2017.08.003_bb0110) 2013; 457 Jarvenpaa (10.1016/j.ejps.2017.08.003_bb0120) 1983; 72 The European Commision. Better Medicines for Children From Concept to Reality (10.1016/j.ejps.2017.08.003_bb0175) 2013; 443 European Medicines Agency (10.1016/j.ejps.2017.08.003_bb0085) 2007 Sassene (10.1016/j.ejps.2017.08.003_bb0165) 2016; 7 Furix (10.1016/j.ejps.2017.08.003_bb0100) U.S.Department of Health and Human Services Food and Drug Administration (10.1016/j.ejps.2017.08.003_bb0180) 2005 Sassene (10.1016/j.ejps.2017.08.003_bb0160) 2014; 16 Granero (10.1016/j.ejps.2017.08.003_bb0105) 2010; 99 U.S.Department of Health and Human Services Food and Drug Administration (10.1016/j.ejps.2017.08.003_bb0185) Administration USDoHaHSFaD (10.1016/j.ejps.2017.08.003_bb0010) 2014 Carriere (10.1016/j.ejps.2017.08.003_bb0055) 2016; 125 Williams (10.1016/j.ejps.2017.08.003_bb0190) 2012; 101 Berthelsen (10.1016/j.ejps.2017.08.003_bb0035) 2016 European Medicines Agency (10.1016/j.ejps.2017.08.003_bb0090) Administration USDoHaHSFaD (10.1016/j.ejps.2017.08.003_bb0015) 2016 Armand (10.1016/j.ejps.2017.08.003_bb0025) 1996; 40 Frusol (10.1016/j.ejps.2017.08.003_bb0095) Kamstrup (10.1016/j.ejps.2017.08.003_bb0125) 2016 Amidon (10.1016/j.ejps.2017.08.003_bb0020) 1995; 12 Beermann (10.1016/j.ejps.2017.08.003_bb0030) 1986; 29 Dressman (10.1016/j.ejps.2017.08.003_bb0065) 1998; 15 Mason (10.1016/j.ejps.2017.08.003_bb0135) 1962; 37 Otsuka (10.1016/j.ejps.2017.08.003_bb0150) 2015; 67 Engle (10.1016/j.ejps.2017.08.003_bb0075) 1978; 62 Buck (10.1016/j.ejps.2017.08.003_bb0050) 2009; 15 Administration USDoHaHSFaD (10.1016/j.ejps.2017.08.003_bb0005) 2001 European Medicines Agency (10.1016/j.ejps.2017.08.003_bb0080) 2006 Kassab (10.1016/j.ejps.2017.08.003_bb0130) 2015; 11 Porter (10.1016/j.ejps.2017.08.003_bb0155) 2007; 6 Takacs-Novak (10.1016/j.ejps.2017.08.003_bb0170) 2013; 83 Zisowsky (10.1016/j.ejps.2017.08.003_bb0195) 2010; 2 Bourlieu (10.1016/j.ejps.2017.08.003_bb0045) 2014; 54 Boehm (10.1016/j.ejps.2017.08.003_bb0040) 1997; 71 Encrantz (10.1016/j.ejps.2017.08.003_bb0070) 1959; 4 Hens (10.1016/j.ejps.2017.08.003_bb0115) 2015; 77 Fernandez (10.1016/j.ejps.2017.08.003_bb2015) 2009; 26 |
References_xml | – volume: 83 start-page: 279 year: 2013 end-page: 285 ident: bb0170 article-title: Biorelevant solubility of poorly soluble drugs: rivaroxaban, furosemide, papaverine and niflumic acid publication-title: J. Pharm. Biomed. Anal. – start-page: 2016 year: March 2016 ident: bb0015 article-title: Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Study Plans. Guidance for Industry. Draft Guidance. Draft Guidance – volume: 15 start-page: 11 year: 1998 end-page: 22 ident: bb0065 article-title: Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms publication-title: Pharm. Res. – volume: 457 start-page: 327 year: 2013 end-page: 332 ident: bb0110 article-title: gastrointestinal model (TIM) with predictive power, even for infants and children? publication-title: Int. J. Pharm. – volume: 67 start-page: 651 year: 2015 end-page: 665 ident: bb0150 article-title: Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach publication-title: J. Pharm. Pharmacol. – volume: 2 start-page: 364 year: 2010 end-page: 388 ident: bb0195 article-title: Drug development for pediatric populations: regulatory aspects publication-title: Pharmaceutics. – volume: 12 start-page: 413 year: 1995 end-page: 420 ident: bb0020 article-title: A theoretical basis for a biopharmaceutic drug classification: the correlation of publication-title: Pharm. Res. – volume: 72 start-page: 677 year: 1983 end-page: 683 ident: bb0120 article-title: Feeding the low-birth-weight infant. III. Diet influences bile acid metabolism publication-title: Pediatrics – volume: 101 start-page: 3360 year: 2012 end-page: 3380 ident: bb0190 article-title: Toward the establishment of standardized publication-title: J. Pharm. Sci. – volume: 443 year: 2013 ident: bb0175 article-title: Progress Report on the Paediatric Regulation (EC) N1901/2006. Com (2013) – year: 2015 ident: bb0185 article-title: Pediatric product development – volume: 29 start-page: 725 year: 1986 end-page: 727 ident: bb0030 article-title: Reduced bioavailability and effect of furosemide given with food publication-title: Eur. J. Clin. Pharmacol. – volume: 4 start-page: 793 year: 1959 end-page: 799 ident: bb0070 article-title: On the bile acids in duodenal contents of infants and children bile acids and steroids 72 publication-title: Clin. Chim. Acta – year: 2006 ident: bb0080 article-title: EC Regulation No 1901/2006 of the European Parliament and of the council of 12 December 2006 on medicinal products for paediatric use and amending regulation (EEC) No 1768/92, directive 2001/20/EC, directive 2001/83/EC and regulation (EC) No 726/2004 publication-title: Off. J. Eur. Union – volume: 11 year: 2015 ident: bb0130 article-title: Diuretics for transient tachypnoea of the newborn publication-title: Cochrane Database Syst. Rev. – volume: 71 start-page: 207 year: 1997 end-page: 214 ident: bb0040 article-title: Bile acid concentrations in serum and duodenal aspirates of healthy preterm infants: effects of gestational and postnatal age publication-title: Biol. Neonate – start-page: 773 year: 2016 end-page: 790 ident: bb0035 article-title: et al. publication-title: Evaluating Oral Drug Delivery Systems: Digestion models Analytical Techniques in the Pharmaceutical Sciences – year: 2014 ident: bb0010 article-title: General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products. Guidance for Industry. Draft guidance – volume: 105 start-page: 876 year: 1993 end-page: 888 ident: bb0060 article-title: Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans publication-title: Gastroenterology – volume: 99 start-page: 2544 year: 2010 end-page: 2556 ident: bb0105 article-title: Biowaiver monographs for immediate release solid oral dosage forms: furosemide publication-title: J. Pharm. Sci. – volume: 7 start-page: 3989 year: 2016 end-page: 3998 ident: bb0165 article-title: Comparison of lipases for publication-title: Food Funct. – year: 2007 ident: bb0085 article-title: The European Paediatric Initiative: History of the Paediatric Regulation. Doc Ref: EMEA/17967/04 Rev 1 – year: 2016 ident: bb0090 article-title: Paediatric regulations – volume: 16 start-page: 1344 year: 2014 end-page: 1357 ident: bb0160 article-title: Toward the establishment of standardized publication-title: AAPS J. – volume: 6 start-page: 231 year: 2007 end-page: 248 ident: bb0155 article-title: Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs publication-title: Nat. Rev. Drug Discov. – volume: 62 start-page: 811 year: 1978 end-page: 818 ident: bb0075 article-title: The use of furosemide in the treatment of edema in infants and children publication-title: Pediatrics – volume: 77 start-page: 40 year: 2015 end-page: 47 ident: bb0115 article-title: Gastrointestinal behavior of nano- and microsized fenofibrate: publication-title: Eur. J. Pharm. Sci. – volume: 40 start-page: 429 year: 1996 end-page: 437 ident: bb0025 article-title: Effect of human milk or formula on gastric function and fat digestion in the premature infant publication-title: Pediatr. Res. – volume: 8 start-page: 1293 year: 2012 end-page: 1303 ident: bb0140 article-title: Ontogeny of oral drug absorption processes in children publication-title: Expert Opin. Drug Metab. Toxicol. – year: 2005 ident: bb0180 article-title: Guidance for Industry. How to Comply With the Pediatric Research Equity Act. Draft Guidance – year: 2013 ident: bb0100 article-title: 20 – volume: 37 start-page: 387 year: 1962 end-page: 391 ident: bb0135 article-title: Some aspects of gastric function in the newborn publication-title: Arch. Dis. Child. – volume: 26 start-page: 1901 year: 2009 end-page: 1910 ident: bb2015 article-title: In vitro gastrointestinal lipolysis of four formulations of piroxicam ans cannarizine with the self emulsifying excipients Labrosol and Gelucire 44/14 publication-title: Pharm. Res. – volume: 15 year: 2009 ident: bb0050 article-title: Furosemide: a review of its use in infants and children publication-title: Pediatr. Pharmacol. – year: 2015 ident: bb0095 article-title: 20mg/5ml Oral Solution. RosemontPharmaceuticals – year: 2001 ident: bb0005 article-title: Bioanalytical Method Validation – volume: 125 start-page: 297 year: 2016 end-page: 305 ident: bb0055 article-title: Impact of gastrointestinal lipolysis on oral lipid-based formulations and bioavailability of lipophilic drugs publication-title: Biochimie – volume: 54 start-page: 1427 year: 2014 end-page: 1457 ident: bb0045 article-title: Specificity of infant digestive conditions: some clues for developing relevant publication-title: Crit. Rev. Food Sci. Nutr. – year: 2016 ident: bb0125 article-title: model simulating gastro-intestinal digestion in the pediatric population (neonates and young infants) publication-title: AAPS PharmSciTech – ident: bb0145 article-title: Products FAQ – volume: 16 start-page: 1344 issue: 6 year: 2014 ident: 10.1016/j.ejps.2017.08.003_bb0160 article-title: Toward the establishment of standardized in vitro tests for lipid-based formulations, part 6: effects of varying pancreatin and calcium levels publication-title: AAPS J. doi: 10.1208/s12248-014-9672-x – year: 2007 ident: 10.1016/j.ejps.2017.08.003_bb0085 – volume: 8 start-page: 1293 issue: 10 year: 2012 ident: 10.1016/j.ejps.2017.08.003_bb0140 article-title: Ontogeny of oral drug absorption processes in children publication-title: Expert Opin. Drug Metab. Toxicol. doi: 10.1517/17425255.2012.698261 – volume: 37 start-page: 387 year: 1962 ident: 10.1016/j.ejps.2017.08.003_bb0135 article-title: Some aspects of gastric function in the newborn publication-title: Arch. Dis. Child. doi: 10.1136/adc.37.194.387 – ident: 10.1016/j.ejps.2017.08.003_bb0100 – start-page: 773 year: 2016 ident: 10.1016/j.ejps.2017.08.003_bb0035 article-title: et al. – volume: 72 start-page: 677 issue: 5 year: 1983 ident: 10.1016/j.ejps.2017.08.003_bb0120 article-title: Feeding the low-birth-weight infant. III. Diet influences bile acid metabolism publication-title: Pediatrics doi: 10.1542/peds.72.5.677 – year: 2001 ident: 10.1016/j.ejps.2017.08.003_bb0005 – volume: 77 start-page: 40 year: 2015 ident: 10.1016/j.ejps.2017.08.003_bb0115 article-title: Gastrointestinal behavior of nano- and microsized fenofibrate: in vivo evaluation in man and in vitro simulation by assessment of the permeation potential publication-title: Eur. J. Pharm. Sci. doi: 10.1016/j.ejps.2015.05.023 – year: 2016 ident: 10.1016/j.ejps.2017.08.003_bb0125 article-title: In vitro model simulating gastro-intestinal digestion in the pediatric population (neonates and young infants) publication-title: AAPS PharmSciTech – volume: 125 start-page: 297 year: 2016 ident: 10.1016/j.ejps.2017.08.003_bb0055 article-title: Impact of gastrointestinal lipolysis on oral lipid-based formulations and bioavailability of lipophilic drugs publication-title: Biochimie doi: 10.1016/j.biochi.2015.11.016 – volume: 2 start-page: 364 issue: 4 year: 2010 ident: 10.1016/j.ejps.2017.08.003_bb0195 article-title: Drug development for pediatric populations: regulatory aspects publication-title: Pharmaceutics. doi: 10.3390/pharmaceutics2040364 – year: 2005 ident: 10.1016/j.ejps.2017.08.003_bb0180 – volume: 54 start-page: 1427 issue: 11 year: 2014 ident: 10.1016/j.ejps.2017.08.003_bb0045 article-title: Specificity of infant digestive conditions: some clues for developing relevant in vitro models publication-title: Crit. Rev. Food Sci. Nutr. doi: 10.1080/10408398.2011.640757 – volume: 15 issue: 8 year: 2009 ident: 10.1016/j.ejps.2017.08.003_bb0050 article-title: Furosemide: a review of its use in infants and children publication-title: Pediatr. Pharmacol. – volume: 7 start-page: 3989 issue: 9 year: 2016 ident: 10.1016/j.ejps.2017.08.003_bb0165 article-title: Comparison of lipases for in vitro models of gastric digestion: lipolysis using two infant formulas as model substrates publication-title: Food Funct. doi: 10.1039/C6FO00158K – ident: 10.1016/j.ejps.2017.08.003_bb0185 – volume: 443 year: 2013 ident: 10.1016/j.ejps.2017.08.003_bb0175 – start-page: 2016 year: 2016 ident: 10.1016/j.ejps.2017.08.003_bb0015 – year: 2006 ident: 10.1016/j.ejps.2017.08.003_bb0080 article-title: EC Regulation No 1901/2006 of the European Parliament and of the council of 12 December 2006 on medicinal products for paediatric use and amending regulation (EEC) No 1768/92, directive 2001/20/EC, directive 2001/83/EC and regulation (EC) No 726/2004 publication-title: Off. J. Eur. Union – volume: 6 start-page: 231 issue: 3 year: 2007 ident: 10.1016/j.ejps.2017.08.003_bb0155 article-title: Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd2197 – volume: 101 start-page: 3360 issue: 9 year: 2012 ident: 10.1016/j.ejps.2017.08.003_bb0190 article-title: Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations publication-title: J. Pharm. Sci. doi: 10.1002/jps.23205 – volume: 99 start-page: 2544 issue: 6 year: 2010 ident: 10.1016/j.ejps.2017.08.003_bb0105 article-title: Biowaiver monographs for immediate release solid oral dosage forms: furosemide publication-title: J. Pharm. Sci. doi: 10.1002/jps.22030 – ident: 10.1016/j.ejps.2017.08.003_bb0090 – volume: 26 start-page: 1901 issue: 8 year: 2009 ident: 10.1016/j.ejps.2017.08.003_bb2015 article-title: In vitro gastrointestinal lipolysis of four formulations of piroxicam ans cannarizine with the self emulsifying excipients Labrosol and Gelucire 44/14 publication-title: Pharm. Res. doi: 10.1007/s11095-009-9906-2 – volume: 4 start-page: 793 issue: 6 year: 1959 ident: 10.1016/j.ejps.2017.08.003_bb0070 article-title: On the bile acids in duodenal contents of infants and children bile acids and steroids 72 publication-title: Clin. Chim. Acta doi: 10.1016/0009-8981(59)90030-0 – year: 2014 ident: 10.1016/j.ejps.2017.08.003_bb0010 – ident: 10.1016/j.ejps.2017.08.003_bb0095 – volume: 11 year: 2015 ident: 10.1016/j.ejps.2017.08.003_bb0130 article-title: Diuretics for transient tachypnoea of the newborn publication-title: Cochrane Database Syst. Rev. – volume: 29 start-page: 725 issue: 6 year: 1986 ident: 10.1016/j.ejps.2017.08.003_bb0030 article-title: Reduced bioavailability and effect of furosemide given with food publication-title: Eur. J. Clin. Pharmacol. doi: 10.1007/BF00615967 – volume: 457 start-page: 327 issue: 1 year: 2013 ident: 10.1016/j.ejps.2017.08.003_bb0110 article-title: In vitro gastrointestinal model (TIM) with predictive power, even for infants and children? publication-title: Int. J. Pharm. doi: 10.1016/j.ijpharm.2013.07.053 – volume: 105 start-page: 876 issue: 3 year: 1993 ident: 10.1016/j.ejps.2017.08.003_bb0060 article-title: Secretion and contribution to lipolysis of gastric and pancreatic lipases during a test meal in humans publication-title: Gastroenterology doi: 10.1016/0016-5085(93)90908-U – volume: 83 start-page: 279 year: 2013 ident: 10.1016/j.ejps.2017.08.003_bb0170 article-title: Biorelevant solubility of poorly soluble drugs: rivaroxaban, furosemide, papaverine and niflumic acid publication-title: J. Pharm. Biomed. Anal. doi: 10.1016/j.jpba.2013.05.011 – ident: 10.1016/j.ejps.2017.08.003_bb0145 – volume: 12 start-page: 413 issue: 3 year: 1995 ident: 10.1016/j.ejps.2017.08.003_bb0020 article-title: A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability publication-title: Pharm. Res. doi: 10.1023/A:1016212804288 – volume: 62 start-page: 811 issue: 5 year: 1978 ident: 10.1016/j.ejps.2017.08.003_bb0075 article-title: The use of furosemide in the treatment of edema in infants and children publication-title: Pediatrics doi: 10.1542/peds.62.5.811 – volume: 67 start-page: 651 issue: 5 year: 2015 ident: 10.1016/j.ejps.2017.08.003_bb0150 article-title: Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach publication-title: J. Pharm. Pharmacol. doi: 10.1111/jphp.12365 – volume: 15 start-page: 11 issue: 1 year: 1998 ident: 10.1016/j.ejps.2017.08.003_bb0065 article-title: Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms publication-title: Pharm. Res. doi: 10.1023/A:1011984216775 – volume: 71 start-page: 207 issue: 4 year: 1997 ident: 10.1016/j.ejps.2017.08.003_bb0040 article-title: Bile acid concentrations in serum and duodenal aspirates of healthy preterm infants: effects of gestational and postnatal age publication-title: Biol. Neonate doi: 10.1159/000244419 – volume: 40 start-page: 429 issue: 3 year: 1996 ident: 10.1016/j.ejps.2017.08.003_bb0025 article-title: Effect of human milk or formula on gastric function and fat digestion in the premature infant publication-title: Pediatr. Res. doi: 10.1203/00006450-199609000-00011 |
SSID | ssj0006870 |
Score | 2.3101165 |
Snippet | The aim of the present study was to study the oral performance of furosemide in neonates and young infants using a newly developed in vitro model simulating... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 191 |
SubjectTerms | Digestion Diuretics - chemistry Diuretics - metabolism Drug solubilization Fasting - metabolism Food-Drug Interactions Furosemide Furosemide - chemistry Furosemide - metabolism Gastric Mucosa - metabolism Humans Hydrogen-Ion Concentration In vitro models Infant Infant, Newborn Intestine, Small - metabolism Models, Biological Neonates and young infants Pediatric Powders Solubility Stomach - chemistry Tablets |
Title | Studying furosemide solubilization using an in vitro model simulating gastrointestinal digestion and drug solubilization in neonates and young infants |
URI | https://dx.doi.org/10.1016/j.ejps.2017.08.003 https://www.ncbi.nlm.nih.gov/pubmed/28803922 https://www.proquest.com/docview/1928782038 |
Volume | 109 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELba7YUL4s3yqIyEeqFh48SOs8eqolpAVJVopd4sOx6vUtF0tdlF2gs_g9_LjJNsBYgeOMb2OJZnMp6JZ75h7G3qVGVh6hJIK5nIEGxSWouuiiB_wmY6yynf-ctpMbuQny7V5Q47HnJhKKyy1_2dTo_aum-Z9Ls5WdT15Gs6zcoUXWaBQkqwdbtsL8PTvhyxvaOPn2enW4VclLFmHI1PiKDPnenCvOBqQajdQkckz6F21t_n07_sz3gOnTxg93sDkh91a3zIdqB5xA7OOgTqzSE_v02oag_5AT-7xabePGY_KW6QMpt4IBxLuK49cBI_ipHtMjI5hcLPuW143fDv9Wp5w2O5HN7W17HWF3bObYvtBDWBGoKW4-M9FVHbxnO_XM__nBUna4B-1UMbx2xIzWBroECcJ-zi5MP58SzpSzMkVa6KVSKcAw0KVOkEeKuzwoWsqHKJbA9aCz-VQtoSeyzaPIBepPPKoXtZgEr9FPKnbNTcNPCc8WhROBIQKaUKqQMVgg4ePVenldVjJgaGmKrHLafyGd_MEKB2ZYiJhphoqKZmmo_Zuy3NokPtuHO0GvhsfpM9g8fKnXRvBqEw-FHSTYvFnVy3Bs3mkoAI83LMnnXSsl1HhhoTxTR78Z9vfcnu0RPlQwr1io1WyzW8RsNo5fbZ7vsfYr8X_18xhhJb |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDCa69LBdhr2bPTVg6GU14pcs51gUK9K1DQosBXoTJJsKXKxuECcD8kf2e0fKdoptWA-7SqIsiBRFWuRHgE-hlYXBsQ0wLNIgdc4EuTHkqkTsT5hYxQnnO59Ps8ll-vVKXu3AUZ8Lw2GVne5vdbrX1l3LqNvN0aKqRt_CcZyH5DJHJKQMW_cAdlMuaj2A3cOT08l0q5Cz3NeM4_EBE3S5M22YF14vGLU7Uh7Js6-d9ff99C_7099Dx0_gcWdAisN2jU9hB-tnsH_RIlBvDsTsLqGqORD74uIOm3rzHH5y3CBnNgnHOJZ4U5UoWPw4RrbNyBQcCj8XphZVLX5Uq-Wt8OVyRFPd-Fpf1Dk3DbUz1ARpCF5O6d-pmNrUpSiX6_mfs9JkNfKvemz8mA2rGWp1HIjzAi6Pv8yOJkFXmiEoEpmtgshaVChR5jbC0qg4sy7OiiQltjulonJMjDA59RiyeZC8SFtKS-5lhjIsx5i8hEF9W-MeCG9RWBaQNE2lCy1K55QryXO1Sho1hKhniC463HIun_Fd9wFq15qZqJmJmmtqhskQPm9pFi1qx72jZc9n_ZvsabpW7qX72AuFpkPJLy2GdnLdaDKbcwYiTPIhvGqlZbuOmDQmGaXx6__86gd4OJmdn-mzk-npG3jEPZwbGcm3MFgt1_iOjKSVfd8dgl-mEhRB |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Studying+furosemide+solubilization+using+an+in+vitro+model+simulating+gastrointestinal+digestion+and+drug+solubilization+in+neonates+and+young+infants&rft.jtitle=European+journal+of+pharmaceutical+sciences&rft.au=Klitgaard%2C+Mette&rft.au=Sassene%2C+Philip+Jonas&rft.au=Selen%2C+Arzu&rft.au=M%C3%BCllertz%2C+Anette&rft.date=2017-11-15&rft.eissn=1879-0720&rft.volume=109&rft.spage=191&rft_id=info:doi/10.1016%2Fj.ejps.2017.08.003&rft_id=info%3Apmid%2F28803922&rft.externalDocID=28803922 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0928-0987&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0928-0987&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0928-0987&client=summon |